Abstract: The present subject matter relates to techniques for systems and methods for determining alpha phase in brain of subjects undergoing depressive disorder. The disclosed system for a closed-loop operation in simultaneous functional magnetic resonance imaging (fMRI)-electroencephalogram (EEG)-transcranial magnetic stimulation (TMS), can include a processor that be configured to receive and process a functional magnetic resonance imaging (fMRI) data and/or an extracranial electroencephalogram (EEG) data and/or transcranial magnetic stimulation (TMS) pulse simultaneously.

Abstract: Methods are provided for microbial electrosynthesis of H2 and organic compounds such as methane and acetate. Method of producing mature electrosynthetic microbial populations by continuous culture is also provided. Microbial populations produced in accordance with the embodiments as shown to efficiently synthesize H2, methane and acetate in the presence of CO2 and a voltage potential. The production of biodegradable and renewable plastics from electricity and carbon dioxide is also disclosed.

Abstract: A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture.

Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a structure of wherein Z is aryl or substituted aryl, heteroaryl, or substituted heteroaryl; X is —S—, —S(O)—, or S(O)2—; R20 and R21 are each independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, or halogenated alkyl; one of R22, R23, and R24 is —O— and the others of R22, R23 and R24 are independently —CH2—, or —C(R13)— wherein R13 is alkyl, alkenyl, alkynyl, trialkylsilyl group, or —(CH2)mOR15, wherein R15 is alkyl or an aryl and m is an integer in the range of 1 to 10; and R25 is H, alkyl, substituted alkyl, halogen, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, C1-C3 alkoxy, aryloxy, or —(CH2)qOR17, wherein R17 is alkyl an aryl and q is an integer in the range of 1 to 10.

Abstract: A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture.

Abstract: A method of making engineered tissue from a plurality of cell aggregates is disclosed. A cell suspension is centrifuged. The resulting pellet is extruded through an orifice, and the extruded pellet is cut into pieces to produce cell aggregates. A plurality of the cell aggregates are printed in a pattern, and allowed to fuse to form a desired three-dimensional engineered tissue structure. Modeling methods predict the structural evolution of fusing cell aggregates for combinations of cell type to enable selection of organ printing process parameters for use in producing an engineered tissue having a desired three-dimensional structure.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

Abstract: Disclosed are articles, compositions and methods for detecting analytes. The disclosed articled, compositions and methods increase the ease of detection and quantitation of the target analyte.

Abstract: Disclosed herein are methods of and systems for predicting recurrence of atrial fibrillation comprising protease and protease inhibitor profiling.

Abstract: Disclosed are methods and materials for assessing cardiac disease, including cardiac failure, cardiac hypertrophy, thoracic aortic aneurysm, left ventricular remodeling using microRNA levels. The level of microRNAs can be measured in a body fluid, such as plasma and serum, or in cardiac tissue.

Abstract: Disclosed are delivery systems that can be used for treating cancer. The delivery systems include a delivery vehicle in conjunction with a chemo-adjuvant. The chemo-adjuvant can enhance the efficacy of a therapeutic agent that can be delivered in conjunction with the delivery vehicle or can be delivered independently of the delivery vehicle.

Abstract: Embodiments of the disclosure are related to systems and methods for utilizing biomarker panel data with respect to medical devices and methods, amongst other things. In an embodiment, the disclosure can include a method of predicting the likelihood of response to CRT therapy. The method can include quantifying levels of one or more biomarkers in a biological sample of a patient, analyzing the quantified levels to determine response to CRT therapy, wherein a panel of biomarkers includes at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. Other embodiments are also included herein.

Abstract: In accordance with certain embodiments of the present disclosure, a kit is described. The kit includes primed living cells joined to and at least partially within a three-dimensional hydrogel structure and an isolated polypeptide having the carboxy-terminal amino acid sequence of an alpha Connexin, or a conservative variant thereof, wherein the polypeptide does not include the full length alpha Connexin protein.

Abstract: Embodiments of the disclosure are related to systems and methods for utilizing biomarker panel data and related medical devices and methods, amongst other things. An embodiment can include a method of screening patients. The method can include quantifying levels of one or more of a panel of biomarkers in a biological sample of a patient. The method can further include analyzing the quantified levels. In some embodiments, the panel of biomarkers includes at least two selected from the group consisting of CRP, SGP-130, sIL-2R, sTNFR-II, IFNg, BNP, sST2, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-4. In an embodiment, the disclosure can include a method of diagnosing a patient. The method can include quantifying levels of one or more of a panel of biomarkers in a biological sample of a patient. The method can further include diagnosing the patient based at least in part on the quantified levels.

Abstract: Disclosed are lipids, annexin, and lipid-annexin complexes for use in the prevention and/or treatment of ischemia-reperfusion injury and reperfusion injury associated with a variety of diseases and conditions. Also disclosed are therapeutic targets and compositions for the prevention and treatment of ischemia-reperfusion injury and diseases and conditions associated with ischemia-reperfusion injury.

Abstract: In accordance with certain embodiments of the present disclosure, a kit is described. The kit includes primed living cells joined to and at least partially within a three-dimensional hydrogel structure and an isolated polypeptide having the carboxy-terminal amino acid sequence of an alpha Connexin, or a conservative variant thereof, wherein the polypeptide does not include the full length alpha Connexin protein.

Abstract: Compositions, methods and kits are provided for treating a cancer, tumor or pre-cancerous tissue condition resistant to a chemotherapeutic agent, the tissue condition having one or more proteins or tumorigenesis markers induced by, upregulated by or otherwise associated with virus exposure. A marker may be a receptor for, or may operatively regulate production or use of hyuronan, for example by mediating a hyaluronan-associated signal path or affecting expression of a protein or signaling pathway of the diseased tissue. A treatment composition includes a competitor of hyaluronan interactions and further includes or is co-administered with a drug, e.g., a chemotherapy agent to which the virus-associated condition would be resistant absent the hyaluronan or competitor.

Abstract: Disclosed are compositions and methods for the treatment of fibrosis. Also disclosed are methods of screening for agents that treat fibrosis.

Abstract: Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.

Abstract: Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.